Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(S)-4-Carboxyphenylglycine
Description: Competitive group I mGlu antagonist; also weak group II agonist
Alternative Names: (S)-4CPG
Purity: ≥99% (HPLC)
Biological Activity for (S)-4-Carboxyphenylglycine
(S)-4-Carboxyphenylglycine is a competitive group I metabotropic glutamate receptor antagonist, with selectivity for mGlu1a/1a over mGlu5a/5b.
Technical Data for (S)-4-Carboxyphenylglycine
| M. Wt | 195.17 |
| Formula | C9H9NO4 |
| Storage | Store at RT |
| Purity | ≥99% (HPLC) |
| CAS Number | 134052-73-6 |
| PubChem ID | 5311459 |
| InChI Key | VTMJKPGFERYGJF-ZETCQYMHSA-N |
| Smiles | [H][C@@](N)(C(O)=O)C1=CC=C(C(O)=O)C=C1 |
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
Solubility Data for (S)-4-Carboxyphenylglycine
| Solvent | Max Conc. mg/mL | Max Conc. mM | |
|---|---|---|---|
| Solubility | |||
| 1eq. NaOH | 19.52 | 100 with gentle warming |
Preparing Stock Solutions for (S)-4-Carboxyphenylglycine
The following data is based on the product molecular weight 195.17. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 5.12 mL | 25.62 mL | 51.24 mL |
| 5 mM | 1.02 mL | 5.12 mL | 10.25 mL |
| 10 mM | 0.51 mL | 2.56 mL | 5.12 mL |
| 50 mM | 0.1 mL | 0.51 mL | 1.02 mL |
Molarity Calculator
Molarity Calculator
Calculate the mass, volume, or concentration required for a solution.
Reconstitution Calculator
Reconstitution Calculator
Dilution Calculator
Dilution Calculator
Calculate the dilution required to prepare a stock solution.
Product Datasheets for (S)-4-Carboxyphenylglycine
References for (S)-4-Carboxyphenylglycine
References are publications that support the biological activity of the product.
Birse et al (1993) Phenylglycine derivatives as new pharmacological tools for investigating the role of metabotropic glutamate receptors in the central nervous system. Neuroscience 52 481 PMID: 7680790
Brabet et al (1995) Phenylglycine derivatives discriminate between mGluR1-and mGluR5-mediated responses. Neuropharmacology 34 895 PMID: 8532171
Doherty et al (1999) Antagonist activity of α-substituted 4-carboxyphenylglycine analogues at group I metabotropic glutamate receptors expressed in CHO cells. Br.J.Pharmacol. 126 205 PMID: 10051137
Eaton et al (1993) Competitive antagonism at metabotropic glutamate receptors by (S)-4-carboxyphenylglycine (CPG) and (RS)-α-methyl-4-carboxyphenylglycine (MCPG). Eur.J.Pharmacol. 244 195 PMID: 8381746
If you know of a relevant reference for (S)-4-Carboxyphenylglycine, please let us know.
View Related Products by Target
View Related Products by Product Action
View all Glutamate (Metabotropic) Group I Receptor Antagonists
Keywords: (S)-4-Carboxyphenylglycine, (S)-4-Carboxyphenylglycine supplier, competitive, Group, I, mGlur, antagonists, weak, group, II, agonists, Competitive, Receptors, mGlu2, mGlu3, mGluR2, mGluR3, Glutamate, Metabotropic, mGlu1, mGlu5, mGluR1, mGluR5, (S)-4CPG, (Metabotropic), 0323, Tocris Bioscience
7 Citations for (S)-4-Carboxyphenylglycine
Citations are publications that use Tocris products. Selected citations for (S)-4-Carboxyphenylglycine include:
Overocker and Pfau (2012) Cytokine Production Modified by System X(c)- After PM10 and Asbestos Exposure. Proc Natl Acad Sci U S A 23 34 PMID: 23418405
Riz et al (2016) Noncanonical SQSTM1/p62-Nrf2 pathway activation mediates proteasome inhibitor resistance in multiple myeloma cells via redox, metabolic and translational reprogramming. Oncotarget 7 66360 PMID: 27626179
Griffin et al (2015) Repeated cycles of chronic intermittent ethanol exposure increases basal glutamate in the nucleus accumbens of mice without affecting glutamate transport. Front Pharmacol 6 27 PMID: 25755641
Resch et al (2014) Augmented cystine-glutamate exchange by pituitary adenylate cyclase-activating polypeptide signaling via the VPAC1 receptor. Synapse PMID: 25066643
Mahler et al (2014) Modafinil attenuates reinstatement of cocaine seeking: role for cystine-glutamate exchange and metabotropic glutamate receptors. J Young Investig 19 49 PMID: 23017017
Liu et al (2007) Cystine-glutamate transporter SLC7A11 mediates resistance to geldanamycin but not to 17-(allylamino)-17-demethoxygeldanamycin. Mol Pharmacol 72 1637 PMID: 17875604
Porter et al (2005) Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J Pharmacol Exp Ther 315 711 PMID: 16040814
Do you know of a great paper that uses (S)-4-Carboxyphenylglycine from Tocris? Please let us know.
Reviews for (S)-4-Carboxyphenylglycine
Average Rating: 4 (Based on 1 Review.)
Have you used (S)-4-Carboxyphenylglycine?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
(S)-4-carboxyphenylglycine (CPG)(0.2 uM).
By
Anonymous on 12/11/2019
Assay Type: In Vitro
Species: Human
Cell Line/Tissue: LP-1 cell line
Treatment with (S)-4-carboxyphenylglycine (CPG) ensitizes LP-1/Cfz cells. Cellswere treated with the indicated concentrations of carfilzomib for 72 hours in the absence or presence of CPG (0.2 uM)
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Addiction Poster
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Depression Poster
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Huntington's Disease Poster
Huntington's disease (HD) is a severe monogenic neurodegenerative disorder, which is characterized by the prevalent loss of GABAergic medium spiny neurons (MSN) in the striatum. This poster summarizes the effects of mutant huntingtin aggregation implicated in the pathology of HD, as well as highlighting the use of iPSCs for HD modeling.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.